We studied the changes in serum fibroblast growth factor-21 (FGF-21) concentrations, its mRNA, and protein expression in skeletal muscle and adipose tissue of 15 patients undergoing cardiac surgery. Blood samples were obtained: prior to initiation of anesthesia, prior to the start of extracorporeal circulation, upon completion of the surgery, and 6, 24, 48, and 96 hours after the end of the surgery.
Introduction
Both experimental and clinical studies have suggested that fibroblast growth factor -21 (FGF-21) plays a role in the regulation of lipid and glucose metabolism and energy homeostasis (Kharitonenkov et al. 2005, Kharitonenkov and Shanafelt 2008) . FGF-21 administration stimulated glucose uptake in mouse adipocytes and in cultures of human adipocytes (Kharitonenkov et al. 2005) . Subcutaneous injection of FGF-21 improved blood glucose and lipid levels in obese mice (Kharitonenkov et al. 2005 ). Long-term administration of FGF-21 to diabetic rhesus monkeys decreased plasma glucose, triglycerides, insulin, and glucagon levels (Kharitonenkov et al.
2007).
According to previous studies, FGF-21 is expressed predominantly in the liver and to a lesser extent in fat (Kharitonenkov et al. 2005 , Mraz et al. 2009 , Nishimura et al. 2000 . In mice, the liver expression of FGF-21 is tightly regulated in response to nutritional status. It is increased by starvation and a ketogenic state and decreased by feeding (Badman et al. 2007 , Inagaki et al. 2005 , Lundasen et al. 2007 . In humans, long-term fasting increased FGF-21 concentrations while a ketogenic diet did not (Galman et al. 2008) . Increased FGF-21 levels were found in patients with type 2 diabetes mellitus and/or obesity relative to healthy subjects, and this was further increased by a short-term very low calorie diet (Mraz et al. 2009 , Zhang et al. 2008 .
Elevated FGF-21 levels were also independently associated with increased risk of metabolic syndrome (Zhang et al. 2008) .
In contrast to subjects with obesity and type 2 diabetes mellitus, patients with decreased body fat content, such as chronically malnourished patients with anorexia nervosa, were characterized by significantly lower serum concentrations of FGF-21 --4 relative to healthy age-matched controls in one study (Dostálová et al. 2008) , while in another study FGF-21 levels in anorexia nervosa patients were unchanged compared with healthy controls (Fazeli et al. 2009 ).
Critically ill patients represent another patient population that suffers from insulin resistance and hyperglycemia in a similar manner to those with type 2 diabetes (Van den Berghe 2002) . Recent studies indicated the beneficial effect of improved glucose control after continuous intravenous insulin treatment, yet an optimal glucose range target is still unclear and differs in various types of patients (Blaha et al. 2009 , Van den Berghe et al. 2001 , Finfer et al. 2009 ). Although the cause of insulin resistance in critically ill patients differs from the cause in patients with type 2 diabetes mellitus, common mechanisms still exist including the development of liver insulin resistance and overproduction of proinflammatory factors by adipose tissue (Kremen et al. 2006 , Mazurek et al. 2003 . Since it has been suggested that FGF-21 is a possible regulator of insulin sensitivity and glucose metabolism in patients with type 2 diabetes mellitus, we hypothesized that it also may play a role in the metabolic response in critically ill patients. To this end, we measured epicardial adipose tissue, subcutaneous adipose tissue, and skeletal muscle mRNA expression of FGF-21 in patients undergoing elective cardiac surgery and studied the dynamics of its serum concentration changes both during and after the surgery.
Methods

Study subjects
This study included 15 male patients who underwent aorto-coronary bypass surgery with extracorporeal circulation. All of the patients participating in the study had arterial hypertension, ischemic heart disease, and BMI ≥ 25. None of the patients --5 had diagnosis of diabetes mellitus or suffered from acute or chronic kidney injury, malignancy, thyroid disease, or acute infection. Seven patients had hyperlipidemia treated by atorvastatin (five patients) or fluvastatin (two patients), respectively. None of the study subject was treated by metformin or fibrate. We used ATP panel III criteria for diagnosis of metabolic syndrome.
All of the patients ate the last meal at 6 PM on the day before the surgery. The surgery was performed after an overnight fasting and it was started between 7-8 AM in all subjects. The average duration of surgery was 252 ± 31 minutes.
Three of the patients received infusion of dobutamine and norepinephrine during and after surgery with maximal dose 7 µg/kg/min and 0.2 µg/kg/min, respectively with treatment duration from 14 to 31 hours. Glucose infusion was not administered in any of the patient. Anthropometric examination, blood and tissue sampling Anthropometric examination of the patients was performed at basal state one day prior to the surgery. All subjects were measured and weighted in light clothes without shoes using standardized scales and BMI was calculated (weight (kg) / height (m) 2 ). Body surface area was calculated using the DuBois and DuBois formula that is routinely used in cardiac surgery patients. Waist circumference was measured by No glucose infusion was administered in any of the patients during the study.
No insulin was administered during the surgery. Insulin administration was initiated --7 in postoperative intensive care unit only in patients with blood glucose exceeding 9.9 mmol/l after surgery. Insulin (Actrapid HM, Novo Nordisk, Baegsvard, Denmark) was given via central venous line as a continuous infusion. A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. Target glucose range was 6.0 -9.9 mmol/l. Normal oral food intake was started in 18 to 24 hours after surgery in all study subjects.
Hormonal and biochemical assays
Plasma samples for measurement of FGF-21 concentrations were diluted with Dilution Buffer 1:1 and measured using a commercial ELISA kit (BioVendor, Modrice, Czech Republic) which is based on the polyclonal anti-human FGF-21
antibody and biotin-labelled polyclonal anti-human FGF-21 antibody. Diluted sera, standards, and quality controls were prepared according to the manufacturer's protocol. Absorbance was measured at 450 nm. A standard curve was constructed by plotting absorbance values against concentrations of standards (8 standards with concentration range 15-1920 pg/ml), and concentrations of samples were calculated using this standard curve. Sensitivity of the kit was 7.0 pg/ml and the intra-and interassay variability of the kit was 3.0 -4.1% and 10%, respectively. Serum C-reactive protein (CRP) levels were measured by high sensitive assay (Bender Medsystems, Vienna, Austria) with a sensitivity of 3 pg/ml. The intra-and inter-assay variability of the kit was less than 5% and less than 10%, respectively. Serum insulin concentrations were measured by commercial RIA kit (Cis Bio International, Gif-surYvette, France) with a sensitivity of 2.0 µIU/ml. The intra-and inter-assay variability of the kits was less than 5% and less than 10%, respectively.
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Serum concentrations of interleukin-6 (IL-6), interleukin-8 (IL-8), tumor necrosis factor-alpha (TNF-alpha), and monocyte chemotactic protein-1 (MCP-1)
were measured using Human serum adipokine LINCOplex Kit (panel B) on a Luminex200 instrument (Linco Research, St. Charles, MO, USA). Sensitivity was 1.6 pg/ml for IL-6, 0.2 pg/ml for IL-8, 0.14 pg/ml for TNF-alpha, and 0.14 pg/ml for MCP-1, respectively. Intra-and inter-assay variability of the kits was 7.8% and 18%
for IL-6, 7.9% and 15% for IL-8, 7.8% and 16% for TNF-alpha, 7.8% and 16% for 
Results
Clinical characteristics of the patients Table 1 shows the clinical characteristics of the entire group of patients and the subgroups with or without insulin administration after the surgery. All patients were males with mean waist circumference 103 ± 3.4 cm, mean baseline blood glucose 6.1 ± 0.29 mmol/l, and mean glycated hemoglobin 4.07 ± 0.10%. All the statistically significant differences between insulin-treated group (IT subgroup) and group without insulin treatment (NT subgroup). are summarized in Table 1 . To further investigate the influence of insulin administration on serum FGF-21 levels we subdivided our patient population into two subgroups: with (n=8) or without (n=7) exogenous insulin administration. At baseline no significant differences in blood glucose, serum insulin, and FGF-21 levels were found between the insulintreated vs. insulin-untreated group. Serum FGF-21 levels tended to be higher in the insulin treated vs. insulin-untreated subgroup throughout all time-points. A significantly higher FGF-21 level in insulin-treated relative to insulin untreated patients was found 48 hours after the end of surgery [222 (120 -581) Figure 3C ). In contrast, the surgery induced a significant increase in FGF-21 mRNA expression in epicardial adipose tissue, whereas the surgery did not significantly change FGF-21 mRNA expression in subcutaneous adipose tissue ( Figure 3A, B) .
Changes of FGF-21 protein expression
In skeletal muscle FGF-21 protein expression was 4.7-fold higher (p = 0,014) than that of subcutaneous fat depot at the start of the surgery ( Figure 3D ). 
Relationship of FGF-
Discussion
Our study demonstrated that serum FGF-21 concentration and its gene expression in epicardial adipose tissue significantly increased after major elective cardiac surgery. Another important finding of this study is that baseline FGF-21 mRNA gene expression and protein expression in skeletal muscle was significantly higher than in subcutaneous and epicardial adipose tissue depots suggesting that skeletal muscle could also represent an important source of this factor.
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Previous studies demonstrated that FGF-21 administration, or its overexpression, exerts a strong glucose and lipid lowering effect in rodents and primates with obesity and type 2 diabetes mellitus (Kharitonenkov et al. 2005 , Kharitonenkov and Shanafelt 2008 , Kharitonenkov et al. 2007 , Dostalova et al. 2008 . Interestingly, human studies have demonstrated that patients with obesity, both with and without type 2 diabetes mellitus, are characterized by increased FGF-21 compared to healthy lean subjects (Mraz et al. 2009 , Zhang et al. 2008 , Chen et al. 2008 . FGF-21 administration also improved β-cell function in experimental studies (Wente et al. 2006) .
In this study we demonstrate that an elective cardiac surgery that induces hyperglycemia, hyperinsulinemia and systemic inflammatory response is accompanied by marked early increase of circulating FGF-21 levels with very similar dynamics to that of insulin and TNF-alpha level. Interestingly, after subdividing our patients into an insulin-treated vs. insulin-untreated group we found significantly higher area under the curve of circulating FGF-21 levels in the former group. The muscle FGF-21 mRNA expression at the start of surgery was also significantly higher in the group that required insulin infusion during a postoperative course. Numerous factors induced by cardiac surgery could have contributed to the increase of FGF-21 levels. Our data showing more pronounced FGF-21 increase after surgery in patients receiving insulin suggest that either insulin treatment itself or metabolic changes associated with the need of insulin treatment could have contributed to this difference.
Furthermore, a positive association between glucose concentration at the end of surgery and muscle FGF-21 mRNA expression at the end of surgery suggests a possible contribution of these factors to the regulation of muscle FGF-21 mRNA expression.
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The complexity of metabolic changes and inflammatory response after cardiac surgery did not allow us to unequivocally determine which of the metabolic changes or proinflammatory factors were responsible for increased FGF-21 concentrations. In multiple regression analysis we were not able to identify any single factor independently associated with a change of circulating FGF-21 levels. Two recent studies albeit performed under different conditions described the presence of FGF-21 mRNA gene expression in skeletal muscle in response to insulin stimulation (Izumiya et al. 2008 , Hojman et al. 2009 ). Here we confirm that human skeletal muscle expresses significant amount of both FGF-21 mRNA and FGF-21 protein.
Interestingly, in contrast to circulating FGF-21 levels muscle FGF-21 mRNA expression was not acutely affected by cardiac surgery suggesting that other tissues were responsible for increased circulating FGF-21 levels.
In original animal studies, the liver was suggested as major producer of this factor while adipose tissue exhibited rather low FGF-21 mRNA expression (Nishimura et al.
2000)
. We have previously demonstrated that liver FGF-21 mRNA expression in patients with obesity is more than 100-fold higher compared to adipose tissue, supporting its important role in FGF-21 production in humans (Mraz et al. 2009 ).
Here we directly compared FGF-21 mRNA and protein expression in fat and skeletal muscle tissues and show that muscle FGF-21 mRNA and protein expression is significantly higher relative to adipose tissue.
Epicardial adipose tissue has been previously identified as a source of inflammatory mediators under basal condition (Mazurek et al.2003 , Baker et al. 2006 aliquotes.
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